ClinicalTrials.gg
CompletedNCT02550977Updated Aug 7, 2017

Russia/Ukraine Suppression of Ovarian Activity Study

A Phase 2 interventional study of Gestodene/EE Patch (BAY86-5016) in Contraception, sponsored by Bayer. Completed at 8 sites in 2 countries. Open to female participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-08-07.

Sponsored by Bayer · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
91
Allocation
Not applicable
Ages
18 Years to 35 Years
Sex
Female
01

Study summary

The purpose of this study is to look into the effectiveness of a new investigational medication applied as a transdermal patch. The patch is applied on the skin with study medication that is absorbed through the skin suppressing ovarian activity and therefore preventing an egg from leaving an ovary (ovulation). The study will look into the study drug's safety and how well it is tolerated and its absorption, breakdown and elimination in the body. It describes how the body affects a specific drug after administration.

02

Conditions studied

  • Contraception

Keywords

  • Contraception
  • Transdermal contraceptive patch
  • Safety
  • Efficacy
  • Pharmacokinetic
03

In context

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy female subjects requesting
  • Aged 18 to 35 years (inclusive); smokers must not be older than 30 years
  • Normal or clinically insignificant cervical smear not requiring further follow-up
  • History of regular cyclic menstrual periods
  • Willingness to use nonhormonal methods of contraception during the entire study
  • Proven ovulation upon completion of the pretreatment cycle

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or lactation
  • Obesity ( [BMI] > 30.0 kg/m2)
  • Significant skin reaction to transdermal preparations or sensitivity to surgical/medical tape
  • Any disease or condition that may worsen under hormonal treatment
  • Use of hormonal other than study medication during the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
91 participants (actual)

Study arms

  • Experimental
    Gestodene/EE Patch

    Drug: Gestodene/EE Patch (BAY86-5016)

Interventions

  • DrugGestodene/EE Patch (BAY86-5016)

    Drug pages: Gestodene · Ethinyl Estradiol

    7 day patch containing 0.55 mg ethinyl estradiol and 2.1 gestodene in a 21 day regimen.

06

What researchers measure

Primary outcomes

  1. Suppression of ovulatory activity proved by progesterone and estradiol concentrations

    Estradiol levels \> 100pmol/L indicate some ovarian activity and progesterone levels \> 5nmol/L in subjects with estradiol levels \> 100pmol/L reflect ovulation or luteinized unruptured follicles.

    Time frame: Treatment day 29 to day 84

Secondary outcomes

  1. Serum concentration, AUC (area under curve) of Gestodene

    Time frame: Multiple time points up to treatment day 84

  2. Serum concentration, AUC (area under curve) of ethinyl estradiol

    Time frame: Multiple time points up to treatment day 84

  3. Serum concentration, AUC (area under curve) of Sexual hormone binding globulin

    Time frame: Multiple time points up to treatment day 84

  4. Number of patients with adverse events

    Time frame: Up to 84 days

  5. Number of patients with abnormal safety laboratory

    Time frame: Up to 84 days

  6. Time course of follicle-stimulating hormone

    Serum concentration of follicle-stimulating hormone (FSH)

    Time frame: Day 27 of pretreatment cycle to treatment day 83

  7. Time course of luteinizing hormone

    Serum concentration of luteinizing hormone (LH)

    Time frame: Day 27 of pretreatment cycle to treatment day 83

07

Study locations

8 sites
  • Irkutsk, 664003, Russian Federation
  • Krasnodar, 350063, Russian Federation
  • Moscow, 115280, Russian Federation
  • Smolensk, 214019, Russian Federation
  • St. Petersburg, 197374, Russian Federation
  • St. Petersburg, 199034, Russian Federation
  • Kiev, 04050, Ukraine
  • Zaporizhzhya, 69068, Ukraine
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2015 to primary completion in Jul 2016, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2015
First posted
Sep 16, 2015
StartActual
Sep 18, 2015
Primary completionActual
Jul 15, 2016
CompletionActual
Aug 15, 2016
Last update
Aug 7, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02550977
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Sep 16, 2015
Start date
Sep 18, 2015
Primary completion
Jul 15, 2016
Completion
Aug 15, 2016
Last update
Aug 7, 2017

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Gestodene · Ethinyl Estradiol

Start the discussion